BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 37767237)

  • 1. Lipopolysaccharide triggers exacerbated microglial activation, excessive cytokine release and behavioural disturbances in mice with truncated Fused-in-Sarcoma Protein (FUS).
    Trofimov A; Pavlov D; Goswami A; Gorlova A; Chaprov K; Umriukhin A; Kalueff A; Deykin A; Lesch KP; Anthony DC; Strekalova T
    Brain Behav Immun Health; 2023 Nov; 33():100686. PubMed ID: 37767237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular and behavioural abnormalities in the FUS-tg mice mimic frontotemporal lobar degeneration: Effects of old and new anti-inflammatory therapies.
    de Munter J; Babaevskaya D; Wolters EC; Pavlov D; Lysikova E; V Kalueff A; Gorlova A; Oplatchikova M; Pomytkin IA; Proshin A; Umriukhin A; Lesch KP; Strekalova T
    J Cell Mol Med; 2020 Sep; 24(17):10251-10257. PubMed ID: 32667139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FET proteins TAF15 and EWS are selective markers that distinguish FTLD with FUS pathology from amyotrophic lateral sclerosis with FUS mutations.
    Neumann M; Bentmann E; Dormann D; Jawaid A; DeJesus-Hernandez M; Ansorge O; Roeber S; Kretzschmar HA; Munoz DG; Kusaka H; Yokota O; Ang LC; Bilbao J; Rademakers R; Haass C; Mackenzie IR
    Brain; 2011 Sep; 134(Pt 9):2595-609. PubMed ID: 21856723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuro-Cells therapy improves motor outcomes and suppresses inflammation during experimental syndrome of amyotrophic lateral sclerosis in mice.
    de Munter JPJM; Shafarevich I; Liundup A; Pavlov D; Wolters EC; Gorlova A; Veniaminova E; Umriukhin A; Kalueff A; Svistunov A; Kramer BW; Lesch KP; Strekalova T
    CNS Neurosci Ther; 2020 May; 26(5):504-517. PubMed ID: 31867846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuroprotective effects of the Sigma-1 receptor (S1R) agonist PRE-084, in a mouse model of motor neuron disease not linked to SOD1 mutation.
    Peviani M; Salvaneschi E; Bontempi L; Petese A; Manzo A; Rossi D; Salmona M; Collina S; Bigini P; Curti D
    Neurobiol Dis; 2014 Feb; 62():218-32. PubMed ID: 24141020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of Fused in sarcoma mutations in mice recapitulates the neuropathology of FUS proteinopathies and provides insight into disease pathogenesis.
    Verbeeck C; Deng Q; Dejesus-Hernandez M; Taylor G; Ceballos-Diaz C; Kocerha J; Golde T; Das P; Rademakers R; Dickson DW; Kukar T
    Mol Neurodegener; 2012 Oct; 7():53. PubMed ID: 23046583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Behavioural impairments in mice of a novel FUS transgenic line recapitulate features of frontotemporal lobar degeneration.
    Lysikova EA; Kukharsky MS; Chaprov KD; Vasilieva NA; Roman AY; Ovchinnikov RK; Deykin AV; Ninkina N; Buchman VL
    Genes Brain Behav; 2019 Nov; 18(8):e12607. PubMed ID: 31437340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FUS transgenic rats develop the phenotypes of amyotrophic lateral sclerosis and frontotemporal lobar degeneration.
    Huang C; Zhou H; Tong J; Chen H; Liu YJ; Wang D; Wei X; Xia XG
    PLoS Genet; 2011 Mar; 7(3):e1002011. PubMed ID: 21408206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monomethylated and unmethylated FUS exhibit increased binding to Transportin and distinguish FTLD-FUS from ALS-FUS.
    Suárez-Calvet M; Neumann M; Arzberger T; Abou-Ajram C; Funk E; Hartmann H; Edbauer D; Kremmer E; Göbl C; Resch M; Bourgeois B; Madl T; Reber S; Jutzi D; Ruepp MD; Mackenzie IR; Ansorge O; Dormann D; Haass C
    Acta Neuropathol; 2016 Apr; 131(4):587-604. PubMed ID: 26895297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autophagy regulates amyotrophic lateral sclerosis-linked fused in sarcoma-positive stress granules in neurons.
    Ryu HH; Jun MH; Min KJ; Jang DJ; Lee YS; Kim HK; Lee JA
    Neurobiol Aging; 2014 Dec; 35(12):2822-2831. PubMed ID: 25216585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FUS(1-359) transgenic mice as a model of ALS: pathophysiological and molecular aspects of the proteinopathy.
    Funikov SY; Rezvykh AP; Mazin PV; Morozov AV; Maltsev AV; Chicheva MM; Vikhareva EA; Evgen'ev MB; Ustyugov AA
    Neurogenetics; 2018 Aug; 19(3):189-204. PubMed ID: 29982879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FUS pathology in basophilic inclusion body disease.
    Munoz DG; Neumann M; Kusaka H; Yokota O; Ishihara K; Terada S; Kuroda S; Mackenzie IR
    Acta Neuropathol; 2009 Nov; 118(5):617-27. PubMed ID: 19830439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frontotemporal lobar degeneration and amyotrophic lateral sclerosis: molecular similarities and differences.
    Neumann M
    Rev Neurol (Paris); 2013 Oct; 169(10):793-8. PubMed ID: 24011641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An autopsy case of frontotemporal lobar degeneration with the appearance of fused in sarcoma inclusions (basophilic inclusion body disease) clinically presenting corticobasal syndrome.
    Matsumoto A; Suzuki H; Fukatsu R; Shimizu H; Suzuki Y; Hisanaga K
    Neuropathology; 2016 Feb; 36(1):77-87. PubMed ID: 26227957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The RNA-binding motif 45 (RBM45) protein accumulates in inclusion bodies in amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration with TDP-43 inclusions (FTLD-TDP) patients.
    Collins M; Riascos D; Kovalik T; An J; Krupa K; Krupa K; Hood BL; Conrads TP; Renton AE; Traynor BJ; Bowser R
    Acta Neuropathol; 2012 Nov; 124(5):717-32. PubMed ID: 22993125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nucleation and dissolution mechanism underlying amyotrophic lateral sclerosis/frontotemporal lobar dementia-linked fused in sarcoma condensates.
    Djaja NA; Chang MT; Beinart FR; Morris VM; Ganser LR; Myong S
    iScience; 2023 Apr; 26(4):106537. PubMed ID: 37123224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aberrant interaction between FUS and SFPQ in neurons in a wide range of FTLD spectrum diseases.
    Ishigaki S; Riku Y; Fujioka Y; Endo K; Iwade N; Kawai K; Ishibashi M; Yokoi S; Katsuno M; Watanabe H; Mori K; Akagi A; Yokota O; Terada S; Kawakami I; Suzuki N; Warita H; Aoki M; Yoshida M; Sobue G
    Brain; 2020 Aug; 143(8):2398-2405. PubMed ID: 32770214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Localization of fused in sarcoma (FUS) protein to the post-synaptic density in the brain.
    Aoki N; Higashi S; Kawakami I; Kobayashi Z; Hosokawa M; Katsuse O; Togo T; Hirayasu Y; Akiyama H
    Acta Neuropathol; 2012 Sep; 124(3):383-94. PubMed ID: 22526020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FUS is phosphorylated by DNA-PK and accumulates in the cytoplasm after DNA damage.
    Deng Q; Holler CJ; Taylor G; Hudson KF; Watkins W; Gearing M; Ito D; Murray ME; Dickson DW; Seyfried NT; Kukar T
    J Neurosci; 2014 Jun; 34(23):7802-13. PubMed ID: 24899704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new subtype of frontotemporal lobar degeneration with FUS pathology.
    Neumann M; Rademakers R; Roeber S; Baker M; Kretzschmar HA; Mackenzie IR
    Brain; 2009 Nov; 132(Pt 11):2922-31. PubMed ID: 19674978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.